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In the present issue of Critical Care, John Marshall and
colleagues report on a clinical trial designed to evaluate the
use of an EAA in patients admitted to a medical–surgical
intensive care unit [1]. Endotoxin plays a central role in sepsis
[2,3]. The current ‘gold standard’ for the determination of
endotoxemia is the limulus amebocyte lysate (LAL) assay,
which requires specific expertise to perform and which is
notorious for wide variability in results [4,5]. Would the EAA
evaluated by Marshall and colleagues be more reliable? And
what are the benefits of a reliable test to detect endotoxemia
in critically ill patients?
Potential benefits of reliable endotoxin
detection
Endotoxin, a lipopolysaccharide component of the cell wall of
Gram-negative organisms, is a central component in the
initiation and/or propagation of the septic cascade [2,3].
When endotoxin is administered to experimental animals or to
human volunteers, a physiological and clinical picture
resembling sepsis is produced [6,7].
There are several potential benefits of a reliable,
reproducible, reasonably rapid endotoxin assay in the
management of critically ill patients. The detection of
circulating endotoxin in the blood of patients may signal the
presence of a Gram-negative infection. This result could
theoretically trigger the administration of antibiotic therapy
directed against the Gram-negative bacteria. Also,
endotoxemia can result from translocation of Gram-negative
organisms and/or endotoxin from the terminal ileum and
cecum in the setting of gastrointestinal tract mucosal barrier
dysfunction that has been observed during hypoperfusion of
the gastrointestinal tract [8]. In this setting, the detection of
endotoxemia may signal the necessity for improved
resuscitation and restoration of splanchnic perfusion. Third,
some investigators have speculated that the level of
endotoxin in the circulation may have prognostic ability for
critically ill patients [9–12]. Finally, it has been suggested
that the presence of endotoxemia may identify a population of
patients who could benefit from the administration of
antibodies against endotoxin [13].
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Abstract
The detection of endotoxemia may provide a clue to the cause of sepsis or may indicate translocation
of endotoxin from the gastrointestinal tract. A reliable endotoxin activity assay (EAA) offers the potential
to determine Gram-negative infections in critically ill patients. In addition, a reliable EAA may indicate
the adequacy of gastrointestinal tract perfusion, as well as potentially help to predict morbidity and
mortality. A recent study by Marshall and colleagues, published in the present issue of Critical Care,
evaluated the use of a whole blood EAA in a medical–surgical intensive care unit and found that 58%
of the patients had positive endotoxin assays. However, only 13.5% of the population had a
documented Gram-negative infection. This discrepancy and the observation that translocation and
other causes of endotoxemia may not reflect true Gram-negative infection might severely limit the
clinical utility of this EAA. Further study may better define the potential role of this technique in the
diagnostic evaluation of the critically ill patient.
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Targeted administration of anti-endotoxin
therapy
Endotoxemia has been the target of previous clinical trials
evaluating the potential benefit of binding and/or neutralizing
endotoxin in an attempt to improve the clinical outcome of
patients with a presumed Gram-negative infection [13–15].
Unfortunately, these efforts have so far failed [13]. While this
failure may reflect the inadequacy of the neutralizing agents,
some have questioned whether the lack of efficacy reflected
the variability in endotoxin levels or the actual presence of
endotoxemia in the study population. These observations
prompted speculation that a reliable, rapid endotoxin assay
might identify a population of patients with circulating
endotoxemia who could theoretically benefit from the
administration of an anti-endotoxin treatment strategy. The
current ‘gold standard’ for the determination of endotoxemia
is the LAL assay, which requires specific expertise to perform
and is notorious for a wide variability in results [4,5].
Effective antibiotic therapy of Gram-negative
infections
John Marshall and colleagues showed an association
between endotoxemia and Gram-negative infections in
patients admitted to a medical–surgical intensive care unit
[1]. They evaluated the use of an EAA and compared it with
the ‘gold standard’ LAL assay in standardized whole blood
samples, demonstrating a good correlation. Fifty-eight
percent of the 74 patients studied had endotoxin levels
>50 pg/ml. Proven infection was present in 26% of the
patients on admission to the intensive care unit, while only
13.5% of the patients had culture-proven Gram-negative
infections. These patients with documented Gram-negative
infection had a significantly elevated mean EAA compared
with the mean level in patients without a documented Gram-
negative infection. There was an association between
elevated EAA and Gram-negative infection, sepsis, and an
elevated white blood cell count [1].
If endotoxemia could be reliably detected, it may serve as an
indicator of a Gram-negative infection and may direct the
clinician to administer effective antibiotic therapy directed
against Gram–negative organisms. In an age of increasing
resistance among the microorganisms encountered in the
intensive care unit, it would be advantageous to only
administer broad-spectrum antibiotics directed against
Gram-negative bacteria to those patients who actually have a
Gram-negative infection. Depending on the sensitivity of the
test and the negative predictive value, there may be a
potential to withhold Gram-negative antibiotic therapy in
those patients who did not manifest a positive EAA.
Predicting outcome
There may also be a potential to use an EAA alone or in
combination with other markers to prognosticate the
outcome of patients with sepsis or the systemic inflammatory
response syndrome. In Marshall and colleagues’ small study,
there was no statistically significant association between
admission EAA and shock, mortality, APACHE II level, and
length of stay [1]. Casey and colleagues, however, have
previously demonstrated a greater risk of mortality among
critically ill patients with a high lipopolysaccharide–cytokine
score, in contrast to the lower mortality observed in those
patients who had a lower lipopolysaccharide–cytokine score
[9]. These observations are of interest and certainly merit
further investigation.
Conclusions
The study by Marshall and colleagues was relatively small,
with less than 30% of the study population having a
documented infection. Less than one-half of these
documented infections was caused by Gram-negative
bacteria. Endotoxemia was found five times as often as
documented Gram-negative infection. This demands further
explanation. It may represent contamination of the assay
technique, translocation from the gastrointestinal tract, or
some other phenomenon. Such a large discrepancy indicates
that the EAA tested by Marshall and colleagues may not be
as valuable in detecting or directing antibiotic therapy as the
rapid streptococcal test that is used by many pediatricians in
the evaluation of children with sore throats. An EAA that
could reliably differentiate between the presence and
absence of Gram-negative infection would allow early
initiation of empiric antibiotic therapy directed at the probable
causative organisms. The reliable documentation of
circulating endotoxemia could also help to determine whether
there is a need for anti-endotoxin therapy or for improved
splanchnic circulation. Further study is required before we
can accept either of these conclusions.
Marshall and colleagues have presented us with a new test
to detect endotoxin in the circulating blood. What we now
need is a better definition of what endotoxemia signifies and
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